Document Detail


A multicenter evaluation of levobunolol (Vistagan) in Germany.
MedLine Citation:
PMID:  3054684     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We evaluated the efficacy and safety of 0.5% levobunolol HC1 (Vistagan) in 2,041 glaucoma patients at 143 sites in the Federal Republic of Germany. This study was a 3-month, open-label, noncomparative trial of levobunolol administered twice daily. Eighty-five percent of the patients completed the study period with well-controlled intraocular pressure (IOP). Treatment was discontinued in the remaining 15%: 7% for adverse reactions, 1% for lack of drug efficacy, and 7% for reasons unrelated to the study treatment. Efficacy, ocular drug tolerance, and systemic safety were judged as good to very good in approximately 80% of the patients. This large, postapproval study confirms previous findings of several well-controlled clinical trials indicating that levobunolol is an effective drug for the treatment of elevated IOP and is safe and comfortable for most patients.
Authors:
G D Novack; E P Kelley; J C Lue
Related Documents :
12864764 - Safety of a patented special butterbur root extract for migraine prevention.
19362954 - Malignant pleural mesothelioma: medical treatment update.
21778264 - Blocking candida albicans biofilm formation by bdsf and trans-bdsf.
1914834 - Chondroprotection with chondroitin sulfate.
9928504 - Spondylarthropathy treatment: progress in medical treatment, physical therapy and rehab...
24345794 - Evaluation of the use of classical nucleation theory for predicting intestinal crystall...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study    
Journal Detail:
Title:  Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde     Volume:  197     ISSN:  0030-3755     ISO Abbreviation:  Ophthalmologica     Publication Date:  1988  
Date Detail:
Created Date:  1988-11-30     Completed Date:  1988-11-30     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0054655     Medline TA:  Ophthalmologica     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  90-6     Citation Subset:  IM    
Affiliation:
Department of Ophthalmology Clinical Research, Allergan Pharmaceuticals, Irvine, Calif.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Drug Administration Schedule
Drug Evaluation
Drug Hypersensitivity / etiology
Germany, West
Glaucoma / drug therapy*
Humans
Levobunolol / administration & dosage,  adverse effects,  therapeutic use*
Multicenter Studies as Topic
Chemical
Reg. No./Substance:
47141-42-4/Levobunolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Combined hamartoma of the retina and retinal pigment epithelium of the juxtapapillary retina and opt...
Next Document:  Lens implantation in children.